Microbiota‐dependent metabolite trimethylamine‐N‐oxide is associated with disease severity and survival of patients with chronic heart failure
Open accessAbstract
Objectives: Recent metabolomic, experimental and clinical studies have demonstrated that trimethylamine‐N‐oxide (TMAO), a microbiota‐dependent metabolite from dietary phosphatidylcholine and carnitine, is a strong predictor of coronary artery disease (CAD). This finding suggests a link between the gut microbiota and atherosclerosis. The potential impact of TMAO in chronic heart failure (HF) is unknown. We hypothesized that TMAO levels would provide prognostic information about adverse outcomes in chronic HF. Design: Prospective, observational study including 155 consecutive patients with chronic HF. In addition, 100 patients with stable CAD without HF and 33 matched healthy individuals were included as controls. Plasma levels of TMAO and its precursors choline and betaine were measured, and associations with symptoms, aetiology and transplant‐free survival in the patients with HF were explored. Results: Plasma levels of TMAO (P = 0.01), choline (P < 0.001) and betaine (P < 0.001) were elevated in patients with chronic HF compared to control subjects, with the highest levels in patients with New York Heart Association (NYHA) classes III and IV. Furthermore, TMAO levels were highest in individuals with ischaemic HF, followed by those with stable CAD and nonischaemic HF. TMAO, but not choline or betaine, was associated with reduced transplant‐free survival: approximately 50% of patients in the upper tertile of TMAO levels died or received a heart transplant during 5.2 years of follow‐up (unadjusted Cox‐regression: hazard ratio 2.24, 95% confidence interval 1.28–3.92, P = 0.005). Conclusions: TMAO levels were elevated in patients with HF and associated with NYHA class, ischaemic aetiology and adverse outcomes. Future studies should focus on gut microbiota, dietary composition and intestinal dysfunction in relation to TMAO levels and clinical outcome in HF.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 6 cited sources checked · 0 supported · 0 flagged
- Findingown data
Plasma TMAO levels are elevated in patients with chronic heart failure compared with healthy control subjects (P = 0.01).
“Plasma levels of TMAO (P = 0.01), choline (P < 0.001) and betaine (P < 0.001) were elevated in patients with chronic HF compared to control subjects”
Quote in the paperSubstantial claim - Findingown data
The association between TMAO and transplant-free survival was attenuated and no longer significant after forced multivariable adjustment (HR 1.79, 95% CI 0.90-1.79, P = 0.097).
“However, this association was attenuated and no longer significant after forced multivariable adjustment for covariates as described in the Methods (HR 1.79, 95% CI 0.90-1.79,P = 0.097).”
Quote in the paperSubstantial claim- Rests on an assumption: The set of covariates included in the multivariable Cox regression is sufficient to control for confounding of the association between TMAO and survival.
- Findingown data
TMAO levels are highest in patients with ischaemic heart failure, followed by those with stable coronary artery disease and then nonischaemic heart failure.
“Furthermore, TMAO levels were highest in individuals with ischaemic HF, followed by those with stable CAD and nonischaemic HF.”
Quote in the paperNot a substantial claim - Findingown data
Plasma betaine levels are elevated in patients with chronic heart failure compared with healthy control subjects (P < 0.001).
“Plasma levels of TMAO (P = 0.01), choline (P < 0.001) and betaine (P < 0.001) were elevated in patients with chronic HF compared to control subjects”
Quote in the paperNot a substantial claim - Findingown data
Betaine, but not TMAO or choline, is positively associated with CRP level.
“Finally, betaine, but not TMAO and choline, was positively associated with CRP level.”
Quote in the paperNot a substantial claim
- Findingown data
Approximately 50% of patients in the upper tertile of TMAO levels died or received a heart transplant during 5.2 years of follow-up.
“approximately 50% of patients in the upper tertile of TMAO levels died or received a heart transplant during 5.2 years of follow-up”
Quote in the paperSubstantial claim - Findingown data
TMAO, choline, and betaine levels are associated with clinical disease severity as assessed by NYHA classification, with the highest levels in NYHA classes III and IV.
“All three markers were also associated with clinical disease severity as assessed by NYHA classification, with the highest levels in patients with NYHA classes III and IV (Fig. 1).”
Quote in the paperSubstantial claim - Findingown data
Plasma choline levels are elevated in patients with chronic heart failure compared with healthy control subjects (P < 0.001).
“Plasma levels of TMAO (P = 0.01), choline (P < 0.001) and betaine (P < 0.001) were elevated in patients with chronic HF compared to control subjects”
Quote in the paperNot a substantial claim - Findingown data
In unadjusted Cox regression comparing the top tertile against the two lower tertiles, TMAO was associated with reduced transplant-free survival (HR 2.24, 95% CI 1.28-3.92, P = 0.005).
“In unadjusted Cox-regression comparing the top tertile against the two lower tertiles, the hazard ratio (HR) was 2.24 [95% confidence interval (CI) 1.28-3.92,P = 0.005].”
Quote in the paperSubstantial claim - Findingown data
LPS levels are increased in patients with heart failure compared with control subjects (92.3 ± 28.2 vs 79.3 ± 24.7 pg/mL, P = 0.01).
“In this study, we found that LPS levels were increased in patients with HF compared to control subjects (92.3 Æ 28.2 vs. 79.3Æ 24.7 pg mL À1 , P = 0.01).”
Quote in the paperNot a substantial claim - Findingown data
During a median follow-up of 5.2 years, 55 (36%) patients died or underwent heart transplantation.
“During a median follow-up of 5.2 years, 55 (36%) patients died (n = 39) or underwent HTx (n = 16).”
Quote in the paperSubstantial claim - Findingown data
None of the metabolites (TMAO, choline, betaine) is correlated with LV-EF or LV end-systolic volume.
“However, none of the metabolites was correlated with LV-EF or LV end-systolic volume (Table 3).”
Quote in the paperNot a substantial claim - Findingown data
Kaplan-Meier analysis revealed that circulating levels of TMAO, but not choline or betaine, are associated with transplant-free survival.
“Kaplan-Meier analysis revealed that the circulating levels of TMAO, but not of choline or betaine, were associated with transplant-free survival.”
Quote in the paperSubstantial claim - Findingown data
The difference in TMAO levels between ischaemic and dilated cardiomyopathy is also seen in patients with normal eGFR.
“as the difference in TMAO levels between ischaemic and dilated cardiomyopathy was also seen in patients with normal eGFR.”
Quote in the paperSubstantial claim - Findingown data
Survival is reduced in patients in the upper tertile of TMAO levels.
“In particular, survival was reduced in patients in the upper tertile of TMAO levels; approximately, 50% of these patients died or received an HTx during follow-up (Fig. 3).”
Quote in the paperSubstantial claim - Findingown data
Betaine and choline levels are elevated in patients with heart failure independent of aetiology compared with individuals with stable coronary artery disease.
“As shown in Fig. 2, levels of betaine and choline were elevated in patients with HF independent of aetiology, compared to individuals with stable CAD.”
Quote in the paperNot a substantial claim - Findingown data
The difference in survival between tertile one and tertile two of TMAO levels is not significant (P = 0.171).
“Furthermore, although survival appeared to be reduced in tertile one of TMAO levels compared to tertile two, the difference was not significant (P = 0.171).”
Quote in the paperNot a substantial claim - Findingown data
TMAO levels are highest in patients with coronary artery disease-related heart failure, followed by those with stable coronary artery disease and then dilated cardiomyopathy-related heart failure.
“TMAO levels, on the other hand, were highest in patients with CAD-related HF, followed by those with stable CAD and then DCM-related HF.”
Quote in the paperNot a substantial claim - Findingown data
TMAO levels are closely associated with decreased eGFR.
“in this study, we found that TMAO levels were closely associated with decreased eGFR.”
Quote in the paperSubstantial claim - Findingown data
The difference in TMAO levels between patients with coronary artery disease plus heart failure and those with dilated cardiomyopathy remains significant after adjusting for age, gender, BMI, smoking, eGFR, previous myocardial infarction, hypertension, type 2 diabetes, and NYHA class (P = 0.022).
“we also performed an ANCOVA, adjusting for differences in age, gender, BMI, smoking, eGFR, previous MI, hypertension, type 2 diabetes and NYHA class, and found that the differences were still significant (P = 0.022).”
Quote in the paperSubstantial claim - Findingown data
TMAO levels in patients with stable coronary artery disease, dilated cardiomyopathy, and healthy controls are not statistically significantly different.
“although TMAO levels appeared to be higher in patients with stable CAD (mean 12.1 Æ 19.5 lM), compared to those with DCM (mean 9.2 Æ 8.5 lM) and healthy control subjects (mean 7.9 Æ 8.9 lM), the differences were not statistically significant.”
Quote in the paperNot a substantial claim - Findingown data
There is no correlation between TMAO and CRP levels in patients with heart failure.
“there was no correlation between TMAO and CRP levels in patients with HF.”
Quote in the paperNot a substantial claim - Findingown data
TMAO levels are elevated in patients with coronary artery disease-related heart failure compared with those with dilated cardiomyopathy also when restricting the comparison to patients with normal renal function (eGFR >60 mL/min/1.73 m2).
“levels of TMAO were closely associated with impaired kidney function (Table 1) but, importantly, were elevated in patients with CADrelated HF compared to those with DCM (13.5 Æ 18.7 vs. 7.1 Æ 5.6 lM, P < 0.001) also when restricting the comparison to patients with normal renal function (eGFR >60 mL min À1 1.73 m À2 ).”
Quote in the paperSubstantial claim - Findingown data
Patients with heart failure caused by coronary artery disease have elevated levels of TMAO and betaine, but not choline, compared with patients with dilated cardiomyopathy.
“As shown in Fig. 2, patients with HF caused by CAD were characterized by elevated levels of TMAO and betaine, but not choline, compared to patients with DCM.”
Quote in the paperNot a substantial claim - Findingown data
TMAO levels did not correlate with cardiac output or LV-EF.
“as TMAO levels did not correlate with cardiac output or LV-EF”
Quote in the paperNot a substantial claim - Findingown data
TMAO was not significantly elevated in coronary artery disease patients without heart failure compared with control subjects.
“TMAO was not significantly elevated in CAD patients without HF compared to control subjects”
Quote in the paperNot a substantial claim - Interpretationown data
This study is the first to show a correlation between a gut microbiota-dependent metabolite and disease severity in patients with heart failure.
“to the best of our knowledge, this study is the first to show a correlation between a gut microbiotadependent metabolite and disease severity in patients with HF.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The association between TMAO levels and disease severity in patients with heart failure had not been investigated before this study.
- Premisecitation
TMAO formation depends on the presence of an intact gut microbiota.
“The formation of TMA, which is subsequently metabolized to TMAO, depends on the presence of an intact gut microbiota [6]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] source
Not checked in the free run.
- Classified as probably not a substantial claim. 15
- May combine two claims. 20
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingown dataTMAO and choline, but not betaine, are positively associated with age.
“Thirdly, TMAO and choline, but not betaine, were positively associated with age.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataTMAO, but not choline or betaine, is associated with reduced transplant-free survival in patients with chronic heart failure.
“TMAO, but not choline or betaine, was associated with reduced transplant-free survival”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataTMAO, but not choline or betaine, is associated with previous myocardial infarction.
“Secondly, TMAO, but not choline or betaine, was associated with previous MI.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataTMAO, choline, and betaine are positively correlated with NT-proBNP and negatively correlated with eGFR in patients with heart failure.
“TMAO, choline and betaine were all positively correlated with levels of NT-proBNP (a marker of cardiac haemodynamic stress) and negatively with renal function, as assessed by eGFR.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCholine and betaine, but not TMAO, are positively associated with right atrial pressure and E/A ratio, and negatively correlated with cardiac output.
“choline and betaine, but not TMAO, were positively associated with right atrial pressure and E/A ratio, and negatively correlated with cardiac output”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAll three metabolites (TMAO, choline, betaine) are correlated with increased pulmonary capillary wedge pressure and mean pulmonary artery pressure, with stronger correlations for choline and betaine than TMAO.
“All markers were correlated with increased pulmonary capillary wedge pressure and mean pulmonary artery pressure, but the correlation coefficients were stronger for choline and betaine compared to TMAO (Table 3).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataCholine and betaine, but not TMAO, are negatively correlated with estimated cardiac output and positively correlated with mean right atrial pressure and E/A ratio.
“Furthermore, choline and betaine, but not TMAO, were negatively correlated with estimated cardiac output and positively correlated with mean right atrial pressure and E/A ratio (Table 3).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataBetaine levels are negatively correlated with plasma LPS and BMI.
“Betaine levels were in fact negatively correlated with plasma LPS as well as BMI”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThere is a positive association between TMAO levels and plasma carnitine levels in the heart failure patient group (r = 0.24, P = 0.003), which is not significant in the coronary artery disease group without heart failure (r = 0.16, P = 0.106).
“we found a positive association between TMAO levels and plasma levels of carnitine in the HF patient group (r = 0.24, P = 0.003), which was not significant in the CAD group without HF (r = 0.16, P = 0.106).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThere is no correlation between LPS levels and choline or TMAO, and there is an inverse relationship between LPS and betaine (r = -0.20, P = 0.01).
“There was, however, no correlation between levels of LPS and choline or TMAO (r = 0.02 and r = 0.01, respectively), and there was an inverse relationship with betaine levels (r = À0.20,P = 0.01).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataTMAO levels in patients with heart failure of ischaemic origin are significantly raised compared with patients with dilated cardiomyopathy and compared with those with stable coronary artery disease.
“However, TMAO levels in patients with HF of ischaemic origin were significantly raised not only compared to patients with DCM but also compared to those with stable CAD.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataNone of TMAO, choline, or betaine is associated with hypertension, type 2 diabetes, or current smoking.
“None of the metabolites was associated with hypertension, type 2 diabetes or current smoking.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationElevated TMAO levels strongly predict coronary artery disease, at least partly because increased TMAO enhances atherogenesis.
“Recent studies have shown that elevated TMAO levels strongly predict coronary artery disease (CAD), at least partly reflecting the ability of increased levels to enhance atherogenesis [6][7][8]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [6][7][8]
Not checked in the free run.
May combine two claims.
PremisecitationTMAO is produced in the liver from TMA, and TMA is generated exclusively by gut microbiota from dietary phosphatidylcholine, choline, and carnitine.
“Trimethylamine-N-oxide (TMAO) is formed in the liver from trimethylamine (TMA), which is exclusively generated by the gut microbiota from dietary phosphatidylcholine, choline and carnitine [6][7][8].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6][7][8]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationTMAO can also be produced from betaine, which is an oxidation product of choline.
“TMAO may also be generated from betaine, which is an oxidation product of choline [9].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [9] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe prognostic value of choline and betaine depends on a simultaneous elevation of TMAO levels.
“whereas the prognostic values of choline and betaine depend on concomitant elevation of TMAO levels, suggesting links between alterations of the microbiota, dietary composition and atherosclerosis [9].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [9] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenThe study was approved by the regional committee for ethics in medicine and conducted according to the Declaration of Helsinki.
“The study was approved by the regional committee for ethics in medicine and conducted according to the Declaration of Helsinki.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenNo information was available from patient records about the possibility of excessive intake of vitamins, fish oils, antioxidants, or micronutrients.
“No information was available from the patient records of the possibility of excessive intake of vitamins, fish oils, antioxidants or micronutrients.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningMyocardial failure is probably also involved in elevated TMAO levels, and the combination of heart failure and an ischaemic aetiology seems particularly important.
“Hence, although an ischaemic aetiology seems to contribute to the elevated TMAO levels, myocardial failure is probably also involved, and the combination of HF and an ischaemic aetiology seems to be particularly important.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenInformed consent was obtained from all individuals.
“Informed consent was obtained from all individuals.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenA strict and standardized blood sampling protocol with similar conditions for all patients and control subjects was used.
“although we used a strict and standardized blood sampling protocol with similar conditions for all patients and control subjects, the use of nonfasting samples is a limitation of this study.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataAll three markers (TMAO, choline, betaine) are correlated with clinical, haemodynamic, and neurohormonal disease severity, but only TMAO levels are associated with adverse outcomes during follow-up.
“All three markers were correlated with clinical, haemodynamic and neurohormonal disease severity, but only TMAO levels were associated with adverse outcomes during follow-up.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataMulticolinearity in the regression models was evaluated by examining tolerance and variance inflation factor; tolerance was >0.4 and VIF <2.5 for all independent variables.
“Multicolinearity in the regression models was evaluated by examining the tolerance and variance inflation factor (VIF) in linear regression.The tolerance was >0.4 and the VIF <2.5 for all independent variables.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataThe study data show that circulating TMAO levels are elevated in patients with chronic heart failure and are associated with disease severity, ischaemic aetiology, and reduced survival.
“In conclusion, the study data show that circulating levels of the microbiota-dependent metabolite TMAO were elevated in patients with chronic HF, and associated with disease severity, ischaemic aetiology and reduced survival.”
Quote in the paperSubstantial claim- Rests on an assumption: The 155 patients with chronic heart failure included in the study are representative of the broader population of patients with chronic heart failure.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationGenetic variation seems to play a minor role in determining circulating levels of TMAO.
“genetic variation seems to play a minor role in determining the circulating levels of TMAO [15].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe study sample size was relatively small, which limits the ability to draw conclusions from multivariate analyses.
“Finally, the study sample size was relatively small, which limits our ability to draw conclusions from multivariate analyses.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe possibility that dietary differences in intake or the use of antibiotics could have influenced the data cannot be excluded.
“we cannot exclude the possibility that dietary differences in intake or the use of antibiotics could have influenced our data.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductnone givenA predefined composite end-point consisting of all-cause and anticipated mortality (heart transplantation) was used in the analyses.
“A predefined composite end-point consisting of allcause and anticipated mortality [i.e.heart transplantation (HTx)] was used in the analyses.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenA large number of correlation analyses were performed, and they should therefore be interpreted with caution.
“Thirdly, a large number of correlation analyses were performed, and should therefore be interpreted with caution.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe use of nonfasting samples is a limitation of the study.
“the use of nonfasting samples is a limitation of this study.”
Quote in the paperNot a substantial claim
The authors state this as an assumption.
The association between TMAO levels and disease severity in patients with heart failure had not been investigated before this study.
“At present, to our knowledge, the association between TMAO levels and disease severity in patients with HF has not been investigated.”
The paper relies on this without support.
The 155 patients with chronic heart failure included in the study are representative of the broader population of patients with chronic heart failure.
“A total of 155 consecutive patients with stable HF for >6 months, in New York Heart Association (NYHA) functional class II-IV, were included in the study at the Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway (Table 1).”
The paper relies on this without support.
The set of covariates included in the multivariable Cox regression is sufficient to control for confounding of the association between TMAO and survival.
“Cox proportional hazard analysis was used to estimate hazard ratios with a forced and stepwise method including NYHA class, age, hypertension, type 2 diabetes, HF aetiology, eGFR, CRP and NT-proBNP.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TMAO levels are associated with cardiovascular disease risks in a variety of cohorts.
“Numerous recent case–control and longitudinal studies have shown a striking association between trimethylamine N‐oxide (TMAO) levels and cardiovascular disease risks in a variety of cohorts.1, 2, 3, 4, 5, 6, 7, 8, 9, 10”
From Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB (2016) · cites this paper as [7]
In humans, elevated plasma TMAO levels are positively correlated with increased risk for major adverse cardiovascular events.
“In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [55]
TMAO could serve as a biomarker in humans to predict prevalence of CVD and increased incidence of major adverse cardiovascular events.
“In this context, it is thought that TMAO could serve as a biomarker in humans to predict prevalence of CVD and increased incidence of major adverse cardiovascular events (MACE), such as myocardial infarction, stroke and even death [7,14,52,53,54,55].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [55]
Elevated plasma TMAO levels have been found in people at risk of CVD, and these patients usually show greater concentrations of TMAO precursors.
“Indeed, elevated plasma TMAO levels have been found in people at risk of CVD. These patients usually show greater concentrations of the TMAO precursors too.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [55]
Among the prospective studies, 5 studies did not find a significantly elevated RR in the highest category of TMAO levels as compared with the lowest category, in either unadjusted or multivariate-adjusted models among total participants.
“Among the prospective studies, 5 studies10, 13, 19, 20, 23 did not find a significantly elevated RR in the highest category of TMAO levels as compared with the lowest category, in either unadjusted or multivariate‐adjusted models among total participants.”
From Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta‐Analysis of Prospective Studies (2017) · cites this paper as [13]
TMAO exacerbates atherosclerosis in a genetic knockout mouse model.
“TMAO exacerbates atherosclerosis in a genetic knockout mouse model, in part by promoting forward cholesterol transport and by inhibiting reverse cholesterol transport (8, 10, 19, 20).”
TMAO inhibits reverse cholesterol transport.
“TMAO exacerbates atherosclerosis in a genetic knockout mouse model, in part by promoting forward cholesterol transport and by inhibiting reverse cholesterol transport (8, 10, 19, 20).”
TMAO promotes forward cholesterol transport.
“TMAO exacerbates atherosclerosis in a genetic knockout mouse model, in part by promoting forward cholesterol transport and by inhibiting reverse cholesterol transport (8, 10, 19, 20).”
TMA produced by gut microbiota from dietary quaternary amines, mainly choline and carnitine, is associated with atherosclerosis and severe cardiovascular disease.
“This is exemplified by trimethylamine (TMA), a microbial metabolite that is produced by various taxa of the gut microbiota from dietary quaternary amines, mainly choline and carnitine. TMA is absorbed via the intestinal epithelium and further oxidized to trimethylamine N-oxide (TMAO), which was associated with atherosclerosis and severe cardiovascular disease in several independent studies [1–4].”
From Uncovering the trimethylamine-producing bacteria of the human gut microbiota (2017) · cites this paper as [3]
TMA is detected through the GPCR TAAR5 chemosensory receptor, to which TMA binds with high affinity, though TAAR5 does not recognize TMAO.
“It is known that the TMAO precursor, TMA, is detected through the GPCR TAAR5 chemosensory receptor, to which TMA binds with high affinity, though TAAR5 is known not to recognize TMAO177.”
From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [177]
Cites
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,402 · see citing works
Bennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070 · see citing works
Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota
Zhu, Y., Jameson, E., Crosatti, M., Schäfer, H., Rajakumar, K., Bugg, T. D. H., & Chen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316569111 · Cited by 372 · see citing works
Hartiala, J., Bennett, B. J., Tang, W. H. W., Wang, Z., Stewart, A. F. R., Roberts, R., McPherson, R., Lusis, A. J., Hazen, S. L., & Allayee, H. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303252 · Cited by 133 · see citing works
Trimethylamine N-oxide suppresses the activity of the actomyosin motor
Kumemoto, R., Yusa, K., Shibayama, T., & Hatori, K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.06.006 · Cited by 31 · see citing works
Flagged first, then by citations
Research works printed but not linked: 21
- Aukrust P, 2006, Anti‐inflammatory trials in chronic heart failure, Heart Fail Monit, 5, 2
- 10.1007/s00592-011-0333-6 · DOI
- 10.1016/j.jacc.2007.07.016 · DOI · Paper page
- 10.2174/138920009787048374 · DOI
- 10.1097/shk.0b013e318033ebc5 · DOI
- 10.1038/nm.3178 · DOI
- 10.1038/nm.3145 · DOI · Paper page
- 10.1093/eurheartj/ehu002 · DOI · Paper page
- 10.1042/CS20100589 · DOI
- 10.1371/journal.pone.0033038 · DOI
- 10.1016/j.ijcard.2012.04.150 · DOI
- 10.1007/s00394-011-0254-8 · DOI
- 10.2337/dc13-0451 · DOI
- 10.1038/nature09922 · DOI · Paper page
- 10.1093/jn/138.5.914 · DOI
- 10.1128/mBio.00944-13 · DOI
- 10.1073/pnas.1215689109 · DOI · Paper page
- 10.1016/j.jacc.2013.04.070 · DOI
- 10.1093/ndt/gfk056 · DOI · Paper page
- 10.1093/eurheartj/eht467 · DOI
- 10.1016/j.numecd.2010.03.009 · DOI
Cited by
Sorted by citations
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968 · see citing works
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317 · see citing works
Dietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163 · see citing works
Gut microbiota and cardiovascular disease.
Witkowski, M., Weeks, T. L., & Hazen, S. L. (2020) · Circulation Research · doi:10.1161/circresaha.120.316242 · Cited by 1,051 · see citing works
Seldin, M. M., Meng, Y., Qi, H., Zhu, W., Wang, Z., Hazen, S. L., Lusis, A. J., & Shih, D. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002767 · Cited by 911 · see citing works
Postler, T. S., & Ghosh, S. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.008 · Cited by 876 · see citing works
“These observations were further corroborated and extended by subsequent studies from the same group and others (Li et al., 2017; Mente et al., 2015; Tang et al., 2013, 2014, 2015; Trøseid et al., 2015; Wang et al., 2014b).”
ResultDietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789 · see citing works
Romano, K. A., Vivas, E. I., Amador-Noguez, D., & Rey, F. E. (2015) · mBio · doi:10.1128/mbio.02481-14 · Cited by 777 · see citing works
Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M. (2018) · Nutrients · doi:10.3390/nu10101398 · Cited by 631 · see citing works
Schiattarella, G. G., Sannino, A., Toscano, E., Giugliano, G., Gargiulo, G., Franzone, A., Trimarco, B., Esposito, G., & Perrino, C. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx342 · Cited by 563 · see citing works
Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M., & Qi, L. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004947 · Cited by 544 · see citing works
Uncovering the trimethylamine-producing bacteria of the human gut microbiota
Rath, S., Heidrich, B., Pieper, D. H., & Vital, M. (2017) · Microbiome · doi:10.1186/s40168-017-0271-9 · Cited by 515 · see citing works
Trimethylamine <i>N</i> -Oxide, the Microbiome, and Heart and Kidney Disease
Zeisel, S. H., & Warrier, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064732 · Cited by 475 · see citing works
Microbial modulation of cardiovascular disease
Brown, J. M., & Hazen, S. L. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.149 · Cited by 440 · see citing works
Missailidis, C., Hällqvist, J., Qureshi, A. R., Barany, P., Heimbürger, O., Lindholm, B., Stenvinkel, P., & Bergman, P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0141738 · Cited by 338 · see citing works
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans
Koeth, R. A., Lam-Galvez, B. R., Kirsop, J., Wang, Z., Levison, B. S., Gu, X., Copeland, M. F., Bartlett, D., Cody, D. B., Dai, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94601 · Cited by 327 · see citing works
Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway
Geng, J., Yang, C., Wang, B., Zhang, X., Hu, T., Gu, Y., & Li, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.016 · Cited by 297 · see citing works
Schugar, R. C., Shih, D. M., Warrier, M., Helsley, R. N., Burrows, A., Ferguson, D., Brown, A. L., Gromovsky, A. D., Heine, M., Chatterjee, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.077 · Cited by 291 · see citing works
Ke, Y., Li, D., Zhao, M., Liu, C., Liu, J., Zeng, A., Shi, X., Cheng, S., Pan, B., Zheng, L., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.01.007 · Cited by 285 · see citing works
Trimethylamine <i>N</i>-oxide and prognosis in acute heart failure
Suzuki, T., Heaney, L. M., Bhandari, S. S., Jones, D. J. L., & Ng, L. L. (2016) · Heart · doi:10.1136/heartjnl-2015-308826 · Cited by 253 · see citing works
Mueller, D. M., Allenspach, M., Othman, A., Saely, C. H., Muendlein, A., Vonbank, A., Drexel, H., & von Eckardstein, A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.091 · Cited by 217 · see citing works
Rohrmann, S., Linseisen, J., Allenspach, M., von Eckardstein, A., & Müller, D. (2016) · The Journal of Nutrition · doi:10.3945/jn.115.220103 · Cited by 197 · see citing works
Gut Microbiota and Ischemic Stroke: The Role of Trimethylamine N-Oxide
Nam, H. S. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00472 · Cited by 176 · see citing works
Trimethylamine N‐oxide: breathe new life
Subramaniam, S., & Fletcher, C. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13959 · Cited by 171 · see citing works
Lifestyle modifications for preventing and treating heart failure
Aggarwal, M., Bozkurt, B., Panjrath, G., Aggarwal, B., Ostfeld, R. J., Barnard, N. D., Gaggin, H., Freeman, A. M., Allen, K., Madan, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2160 · Cited by 162 · see citing works
Zhu, W., Buffa, J. A., Wang, Z., Warrier, M., Schugar, R., Shih, D. M., Gupta, N., Gregory, J. C., Org, E., Fu, X., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14234 · Cited by 161 · see citing works
3,3-Dimethyl-1-butanol attenuates cardiac remodeling in pressure-overload-induced heart failure mice
Wang, G., Kong, B., Shuai, W., Fu, H., Jiang, X., & Huang, H. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108341 · Cited by 100 · see citing works
Trøseid, M., Hov, J. R., Nestvold, T. K., Thoresen, H., Berge, R. K., Svardal, A., & Lappegård, K. T. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0120 · Cited by 84 · see citing works
Self-citationIntermittent Hypoxia and Hypercapnia Accelerate Atherosclerosis, Partially via Trimethylamine-Oxide
Xue, J., Zhou, D., Poulsen, O., Imamura, T., Hsiao, Y.-H., Smith, T. H., Malhotra, A., Dorrestein, P., Knight, R., & Haddad, G. G. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0086oc · Cited by 77 · see citing works
The Role of Microbiota in Cardiovascular Risk: Focus on Trimethylamine Oxide
Al-Rubaye, H., Perfetti, G., & Kaski, J.-C. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.06.005 · Cited by 43 · see citing works
Destructive Role of TMAO in T-Tubule and Excitation-Contraction Coupling in the Adult Cardiomyocytes
Jin, B., Ji, F., Zuo, A., Liu, H., Qi, L., He, Y., Wang, Q., & Zhao, P. (2020) · International Heart Journal · doi:10.1536/ihj.19-372 · Cited by 30 · see citing works
Wargny, M., Croyal, M., Ragot, S., Gand, E., Jacobi, D., Trochu, J.-N., Prieur, X., Le May, C., Goronflot, T., Cariou, B., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01505-9 · Cited by 21 · see citing works
Bjørndal, B., Ramsvik, M., Lindquist, C., Nordrehaug, J., Bruheim, I., Svardal, A., Nygård, O., & Berge, R. (2015) · Marine Drugs · doi:10.3390/md13095706 · Cited by 20 · see citing works
Self-citation
- Authors
- Trøseid, M., Ueland, T., Hov, J. R., Svardal, A., Gregersen, I., Dahl, C. P., Aakhus, S., Gude, E., Bjørndal, B., Halvorsen, B., Karlsen, T. H., Aukrust, P., Gullestad, L., Berge, R. K., & Yndestad, A.
- Affiliations
- Oslo University Hospital (NO)
- University of Bergen (NO)
- Haukeland University Hospital (NO)
- Corresponding author
- Trøseid, M.
- ORCID
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2014-12
- Volume
- 277
- Issue
- 6
- Pages
- 717-726
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1991855600
- Cited by
- 464
- References
- 5
- Citations by year
- 2026: 19 · 2025: 32 · 2024: 33 · 2023: 47 · 2022: 69 · 2021: 48 · 2020: 45 · 2019: 51 · 2018: 37 · 2017: 41 · 2016: 26 · 2015: 15
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- K.G. Jebsen Centre for Inflammation Research
- Western Norway Regional Health Authority (911802)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
- Keywords
- trimethylamine N-oxide, gut microbiota, chronic heart failure, choline, betaine, transplant-free survival, disease severity, ischemic heart failure, coronary artery disease, prognostic factors, atherosclerosis, L-carnitine
- MeSH terms
- Aged, Betaine, Choline, Chronic Disease, Female, Heart Failure, Humans, Intestinal Mucosa, Intestines, Lipotropic Agents, Male, Methylamines, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Risk Factors, Sensitivity and Specificity, Severity of Illness Index, Biomarkers, Survival Analysis, Oxidants, Risk Assessment, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-05.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-05.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review